Overview
flowchart TD
companies_kyorin_pharmaceutica["Kyorin Pharmaceutical Co., Ltd."]
companies_kyorin_pharmaceutica["Company"]
companies_kyorin_pharmaceutica -->|"related to"| companies_kyorin_pharmaceutica
style companies_kyorin_pharmaceutica fill:#81c784,stroke:#333,color:#000
companies_kyorin_pharmaceutica["Kirin"]
companies_kyorin_pharmaceutica -->|"related to"| companies_kyorin_pharmaceutica
style companies_kyorin_pharmaceutica fill:#81c784,stroke:#333,color:#000
companies_kyorin_pharmaceutica["Kabushiki-gaisha"]
companies_kyorin_pharmaceutica -->|"related to"| companies_kyorin_pharmaceutica
style companies_kyorin_pharmaceutica fill:#81c784,stroke:#333,color:#000
companies_kyorin_pharmaceutica["Japanese"]
companies_kyorin_pharmaceutica -->|"related to"| companies_kyorin_pharmaceutica
style companies_kyorin_pharmaceutica fill:#81c784,stroke:#333,color:#000
style companies_kyorin_pharmaceutica fill:#4fc3f7,stroke:#333,color:#000
Company Overview
Kyorin Pharmaceutical Co., Ltd. (協和キリン株式会社, Kyōrin Kirin Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. The company was established in 1949 and operates as a subsidiary of Kyorin Holdings, Inc. Kyorin focuses on the development and manufacturing of pharmaceutical products primarily in the fields of nephrology, urology, and immunology, with expanding interests in neurology and neurodegenerative diseases.
Corporate Profile
...Overview
Mermaid diagram (expand to render)
Company Overview
Kyorin Pharmaceutical Co., Ltd. (協和キリン株式会社, Kyōrin Kirin Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. The company was established in 1949 and operates as a subsidiary of Kyorin Holdings, Inc. Kyorin focuses on the development and manufacturing of pharmaceutical products primarily in the fields of nephrology, urology, and immunology, with expanding interests in neurology and neurodegenerative diseases.
Corporate Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | Tokyo, Japan |
| Founded | 1949 |
| Stock Ticker | TSE: 4569 |
| Revenue | ¥85.6 billion (FY2023) |
| Employees | ~3,500 |
| CEO | Masahiko Taki |
| Website | www.kyorin-pharm.co.jp |
History and Development
Kyorin Pharmaceutical has evolved through several key phases since its founding:
Early History (1949-1980s)
Founded as Kyorin Seiyaku Co., Ltd., the company initially focused on generic pharmaceutical products. During this period, Kyorin established its manufacturing capabilities and built a domestic distribution network across Japan.
Expansion Phase (1980s-2000s)
In 1988, Kyorin merged with Kirin Brewery's pharmaceutical division, creating the modern Kyorin Pharmaceutical. This merger provided access to Kirin's research capabilities and financial resources, enabling expansion into innovative drug development.
Modern Era (2010s-Present)
Kyorin has shifted focus toward specialty pharmaceuticals, particularly in nephrology and immunology. Recent years have seen increased interest in neurology, including Alzheimer's disease and Parkinson's disease research programs.
Research Focus Areas
Nephrology
Kyorin's primary focus has been on kidney disease treatments. The company's flagship product in this area includes drugs for chronic kidney disease (CKD) and dialysis-related complications.
Immunology
The immunology division develops treatments for autoimmune diseases and inflammatory conditions. This research has potential applications in neuroinflammation, a key component of neurodegenerative diseases.
Neurology (Emerging Focus)
Kyorin has recently entered the neurodegeneration space through academic partnerships and internal research programs targeting:
- Alzheimer's Disease: [Amyloid-beta](/proteins/amyloid-beta) targeting therapies
- Parkinson's Disease: [Alpha-synuclein](/proteins/alpha-synuclein) aggregation inhibitors
- Neuroinflammation: Microglial activation modulators
Key Products and Pipeline
Current Products
Kyorin markets several pharmaceutical products across therapeutic areas:
- Nefecon: Immunosuppressive medication for IgA nephropathy
- Ursosan: Ursodeoxycholic acid formulation for liver and biliary disorders
- Azunol: Gastroprotective agent
Pipeline Candidates
| Compound | Indication | Development Stage | Target |
|----------|------------|-------------------|--------|
| KRM-100 | Alzheimer's Disease | Preclinical | Amyloid-beta |
| KRM-200 | Parkinson's Disease | Preclinical | Alpha-synuclein |
| KRM-300 | Neuroinflammation | Discovery | [TREM2](/proteins/trem2) |
Academic Partnerships
Kyorin collaborates with Japanese universities and research institutions:
- University of Tokyo: Neurodegeneration research
- Kyoto University: Amyloid biology studies
- Tokyo Metropolitan Institute: Parkinson's disease research
- National Center for Neurology and Psychiatry: Clinical research partnerships
International Collaboration
Kyorin has established partnerships with international pharmaceutical companies:
- License agreements with European biotech firms
- Research collaborations with US academic institutions
- Co-development agreements for neurological drug candidates
Kyorin Pharmaceutical has maintained steady financial performance:
- FY2023 Revenue: ¥85.6 billion
- R&D Investment: ¥12.8 billion (15% of revenue)
- Operating Income: ¥18.2 billion
- Market Capitalization: ~¥180 billion
The company has increased R&D spending on neurology programs in recent years, reflecting its strategic interest in neurodegeneration.
Corporate Social Responsibility
Kyorin is committed to healthcare access and research funding:
- Support for patient advocacy groups in Japan
- Research grants for neurodegenerative disease research
- Environmental sustainability programs
- Healthcare provider education initiatives
Future Outlook
Kyorin Pharmaceutical is positioning itself for growth in the neurodegenerative disease market through:
Pipeline Development: Advancing preclinical candidates in AD and PD
Academic Partnerships: Leveraging Japanese neuroscience research excellence
Strategic Acquisitions: Seeking to acquire or license neuroscience assets
International Expansion: Entering global markets for future productsSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Kyorin Pharmaceutical Corporate Website (n.d.)
Unknown, Kyorin Holdings Annual Report 2023 (2023)
Unknown, Kyorin Pharmaceutical TSE Disclosure (n.d.)
Unknown, Japanese Pharmaceutical Companies Directory (n.d.)